Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium salt presented as an intravenous solution for extracorporeal use. It is employed to correct low blood calcium levels and to provide calcium supplementation during dialysis procedures. The formulation is sterile, isotonic and compatible with standard infusion sets, allowing precise titration of calcium ions under clinical supervision.

GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide, ensuring quality‑controlled manufacturing and reliable logistics for critical care settings.

Icalziss is used to manage disorders of calcium balance and to support patients undergoing renal replacement therapy. - Hypocalcemia: restores normal serum calcium concentrations in patients with low calcium levels. - Dialysis-associated calcium deficiency: provides calcium supplementation during hemodialysis to maintain electrolyte stability. - Perioperative calcium depletion: helps maintain calcium homeostasis during surgeries that may cause calcium loss.

Calcium chloride dihydrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion site irritation: redness or pain at the injection site. - Transient hypercalcemia: temporary elevation of serum calcium levels. - Hypotension: drop in blood pressure during rapid infusion. - Nausea or vomiting: gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypercalcemia: can lead to cardiac arrhythmias or renal impairment. - Cardiac arrest: rare but possible with rapid high‑dose administration. - Tissue necrosis: extravasation may cause local tissue damage. - Anaphylactic reaction: rare hypersensitivity requiring immediate treatment.

When using Icalziss, clinicians should observe several safety measures to minimize risks. - Serum calcium monitoring: check calcium levels before and during infusion. - Renal function assessment: adjust dosing in patients with impaired kidney function. - Cardiac status evaluation: observe for arrhythmias, especially in patients with heart disease. - Concurrent blood product infusion: avoid mixing with blood components to prevent precipitation. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcium chloride dihydrate can interact with several medications, influencing calcium balance or drug efficacy.

Major Interactions (Avoid): - Loop diuretics: increase urinary calcium loss, potentially counteracting therapy. - Bisphosphonates: may precipitate severe hypocalcemia when given concurrently. - Calcitonin: additive calcium‑lowering effect, risking hypocalcemia.

Moderate Interactions (Monitor Closely): - Digitalis glycosides: elevated calcium may enhance digitalis toxicity. - ACE inhibitors: monitor blood pressure as calcium can affect vascular tone. - Magnesium sulfate: concurrent use may alter calcium homeostasis.